References
Hillmen P, Young NS, Schubert J et al (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355:1233–1243
Psaty EL, Scope A, Halpern AC, Marghoob AA (2010) Defining the patient at high risk for melanoma. Int J Dermatol 49(4):362–376
Balch CM, Gershenwald JE, Soong S, Thompson JF, Atkins MB, Byrd DR, Buzaid AC et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206
Laroni A, Bedognetti M, Uccelli A, Capello E, Mancardi GL (2011) Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. Neurol Sci 32(1):181–182
Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and risk of malignancy: analyses from a large US observational study. Arch Rheum 56:2886–2895
Askling J, Bongartz T (2008) Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 20:334–339
Conflicts of interest
The authors declare that they have no conflicts of interest to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Manganoni, A.M., Pavoni, L., Facchetti, F. et al. Melanoma in a patient in treatment with eculizumab. Ann Hematol 91, 135–136 (2012). https://doi.org/10.1007/s00277-011-1229-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-011-1229-9